Clinical models for anaerobic bacterial infections in dogs and their use in testing the efficacy of clindamycin and lincomycin.
Two canine models of clinical anaerobic bacterial infections were developed for the study of the clinical parameters associated with these infections and for evaluation of antimicrobial agents that might be useful in therapy. In model I, a mixed culture of Bacteroides fragilis, B melaninogenicus, and Fusobacterium necrophorum was used as the inoculum. In model II, a mixed culture of B fragilis and Clostridium perfringens combined with an infection enhancer (sterile cinder dust) was used as the inoculum. In both models, reproducible localized pyogenic or gangrenous infections were induced. Clinical signs of fever, depression, and leukocytosis with a left shift were present. A depression in the nonspecific cell-mediated immune response was noticed. The 2 models were used to evaluate clindamycin and lincomycin for therapy of anaerobic bacterial infections, using a subjective scoring system for severity of lesions and general clinical appearance. Clindamycin at dosage levels of 5.5 mg or 11 mg/kg of body weight, twice a day was highly efficacious in the treatment of anaerobic bacterial infections in both models. Dogs given lincomycin (22 mg/kg twice a day) responded to the treatment, but the response was less than that seen with clindamycin.
Department of Veterinary Microbiology, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211, USA.
J N
JN
Berg
C M
CM
Scanlan
G M
GM
Buening
W H
WH
Fales
D A
DA
Schmidt
J C
JC
Wilson
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001421:Bacteria, Anaerobic; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D002981:Clindamycin / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D008034:Lincomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice
D000900:Anti-Bacterial Agents; D002981:Clindamycin; D008034:Lincomycin